Mirabella Financial Services LLP Akebia Therapeutics, Inc. Transaction History

Mirabella Financial Services LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $52,240 - $83,584	65,300 New	65,300 $80,000
Q1 2023 May 12, 2023	BUY	$0.56 - $1.15 $78,738 - $161,694	140,604 New	140,604 $78,000
Q2 2022 Aug 12, 2022	SELL	$0.32 - $0.67 $18,016 - $37,721	-56,300 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$0.72 - $2.93 $40,536 - $164,959	56,300 New	56,300 $40,000
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.88 $628,867 - $1.04 Million	-267,603 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$2.83 - $4.2 $567,814 - $842,692	-200,641 Reduced 42.85%	267,603 $1.01 Million
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $1.37 Million - $2.37 Million	468,244 New	468,244 $1.59 Million

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $395M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Mirabella Financial Services LLP, based on Form 13F filings with the SEC.

Stay updated on Mirabella Financial Services LLP with notifications on news.